TRVN
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2024 Q3 | -5.79 | $283,000 | -$5M |
| 2024 Q2 | -5.74 | $325,000 | -$7M |
| 2024 Q1 | -9.01 | $20,000 | -$9M |
| 2023 Q4 | -1.06 | -$81,000 | -$6M |
| 2023 Q3 | -14.20 | $180,000 | -$9M |
| 2023 Q2 | -17.30 | $3M | -$7M |
| 2023 Q1 | -0.42 | $6,000 | -$11M |
| 2022 Q4 | -0.53 | $0 | -$11M |